| Mucosal injury during anti-cancer treatment: from pathobiology to bedside D Basile, P Di Nardo, C Corvaja, SK Garattini, G Pelizzari, C Lisanti, ... Cancers 11 (6), 857, 2019 | 113 | 2019 |
| The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients D Basile, A Parnofiello, MG Vitale, F Cortiula, L Gerratana, V Fanotto, ... Journal of cachexia, sarcopenia and muscle 10 (2), 368-377, 2019 | 74 | 2019 |
| The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients D Basile, A Parnofiello, MG Vitale, F Cortiula, L Gerratana, V Fanotto, ... Journal of cachexia, sarcopenia and muscle 10 (2), 368-377, 2019 | 74 | 2019 |
| Do platinum salts fit all triple negative breast cancers? L Gerratana, V Fanotto, G Pelizzari, E Agostinetto, F Puglisi Cancer treatment reviews 48, 34-41, 2016 | 68 | 2016 |
| Platinum salts in patients with breast cancer: a focus on predictive factors M Garutti, G Pelizzari, M Bartoletti, MC Malfatti, L Gerratana, G Tell, ... International Journal of Molecular Sciences 20 (14), 3390, 2019 | 62 | 2019 |
| Androgen receptor in estrogen receptor positive breast cancer: Beyond expression D Basile, M Cinausero, D Iacono, G Pelizzari, M Bonotto, MG Vitale, ... Cancer treatment reviews 61, 15-22, 2017 | 59 | 2017 |
| Lactate dehydrogenase (LDH) response to first-line treatment predicts survival in metastatic breast cancer: first clues for a cost-effective and dynamic biomarker G Pelizzari, D Basile, S Zago, C Lisanti, M Bartoletti, L Bortot, MG Vitale, ... Cancers 11 (9), 1243, 2019 | 50 | 2019 |
| Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle L Gerratana, M Bonotto, C Bozza, E Ongaro, V Fanotto, G Pelizzari, ... Expert Opinion on Biological Therapy 17 (3), 365-374, 2017 | 34 | 2017 |
| Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application B Posocco, M Buzzo, AS Poetto, M Orleni, S Gagno, M Zanchetta, ... PLoS One 15 (2), e0228822, 2020 | 31 | 2020 |
| Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation G Pelizzari, L Gerratana, D Basile, V Fanotto, M Bartoletti, A Liguori, ... Cancer Treatment Reviews 72, 7-14, 2019 | 31 | 2019 |
| Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis M Bartoletti, G Pelizzari, L Gerratana, L Bortot, D Lombardi, M Nicoloso, ... International Journal of Molecular Sciences 21 (11), 3805, 2020 | 30 | 2020 |
| The MIMIC study: prognostic role and cutoff definition of monocyte‐to‐lymphocyte ratio and lactate dehydrogenase levels in metastatic colorectal cancer D Basile, SK Garattini, C Corvaja, M Montico, F Cortiula, G Pelizzari, ... The oncologist 25 (8), 661-668, 2020 | 27 | 2020 |
| Atezolizumab for the treatment of breast cancer D Basile, G Pelizzari, MG Vitale, C Lisanti, M Cinausero, D Iacono, ... Expert opinion on biological therapy 18 (5), 595-603, 2018 | 23 | 2018 |
| Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly? C Fontanella, E De Carlo, M Cinausero, G Pelizzari, I Venuti, F Puglisi Cancer Treatment Reviews 46, 80-88, 2016 | 23 | 2016 |
| Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study D Basile, M Bartoletti, M Polano, L Bortot, L Gerratana, P Di Nardo, ... Clinical nutrition 40 (1), 286-294, 2021 | 22 | 2021 |
| Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis L Gerratana, D Basile, B Toffoletto, M Bulfoni, S Zago, A Magini, M Lera, ... Scientific Reports 10 (1), 7010, 2020 | 20 | 2020 |
| First-and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: a real-world study D Basile, L Gerratana, C Corvaja, G Pelizzari, G Franceschin, E Bertoli, ... The Breast 57, 104-112, 2021 | 17 | 2021 |
| Prognostic role of disease extent and lymphocyte–monocyte ratio in advanced melanoma D Iacono, D Basile, L Gerratana, MG Vitale, G Pelizzari, M Cinausero, ... Melanoma Research 29 (5), 510-515, 2019 | 17 | 2019 |
| Prognostic role of disease extent and lymphocyte–monocyte ratio in advanced melanoma D Iacono, D Basile, L Gerratana, MG Vitale, G Pelizzari, M Cinausero, ... Melanoma Research 29 (5), 510-515, 2019 | 17 | 2019 |
| Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy E Ongaro, L Gerratana, M Cinausero, G Pelizzari, E Poletto, M Giangreco, ... Future Oncology 14 (9), 849-859, 2018 | 17 | 2018 |
